Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)

Inclusion Criteria: * Male and female patients aged at least 18 years * Mild to moderate active plaque psoriasis with PGA ≥ 2 on the 7-point scale by Langley and Ellis and a Body Surface Area (BSA) of ≤ 10% * Topical psoriasis treatment with coal or tar preparations, tazarotene, steroids, or vitamin D analogues, or combinations of steroids and vitamin D analogues (except gel combination products containing 50 micrograms calcipotriol/0.5mg betamethasone/g) or dithranol and its combination preparations over the last 8 weeks prior to Visit 1 (week 0) * Written informed consent to participate in the study has been given prior to any study related procedures Exclusion Criteria: * Severe renal insufficiency * Severe hepatic disorders * Known hyper calcaemia * Erythrodermic, exfoliative, pustular or guttate psoriasis * Facial or genital psoriasis * Fulfilment of at least one contraindication according to the Summary of Product Characteristics of Daivobet®/Dovobet® Gel * Pregnant and/or breast-feeding women * Hypersensitivity to the active substances or to any of the excipients * Suspected non-compliance with the clinical study procedures * Current participation in another clinical study * Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to Visit 1 (week 0): * etanercept - within 4 weeks prior to Visit 1 (week 0) * adalimumab, alefacept, infliximab - within 2 months prior to Visit 1 (week 0) * ustekinumab - within 4 months prior to Visit 1 (week 0) * experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to Visit 1 (week 0) * Phototherapy within the following time periods prior to Visit 1 (week 0): * PUVA - within 4 weeks prior to Visit 1 (week 0) * UV-B - within 2 weeks prior to Visit 1 (week 0)